Clinical Trials | August 28, 2023
Zydus to present on ZYIL1 at the International Congress of Parkinson's Disease and Movement Disorders
In Phase I studies, ZYIL1 was found to be safe and well-tolerated in human volunteers
In Phase I studies, ZYIL1 was found to be safe and well-tolerated in human volunteers
The company is committed to address the observations and will submit its response to US FDA within the stipulated time
SKYSCRAPER-01 is ongoing and the study remains blinded to patients and investigators
LEO Pharma is developing delgocitinib cream for the treatment of moderate to severe chronic hand eczema, a hard-to-treat disease where there is a high unmet medical need for treatment
Global Initiative on Digital Health launched at the G2O Health Minister’s Meeting
Combating the prevalent stigma against TB in the society, India has been committed to providing, enabling and patient-centric support to all, individuals suffering from TB
Glenmark's current portfolio consists of 184 products authorized for distribution in the U.S. marketplace
Ryan has nearly 20 years of global legal and IP expertise in the pharmaceutical industry
Continuous learning is not just an option but a responsibility that every healthcare professional must shoulder
The instrument is fully integrated with Lonza’s latest WinKQCLSoftware to enable data integrity compliance, streamline training, and reduce validation burden
Subscribe To Our Newsletter & Stay Updated
